Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
As of September 30, 2021 we had Cash of $727,162 and as of September 30, 2020 we had cash of $0.
The increase in Cash is primarily attributable to:
(a) Net increase of $1,363, 00 of Notes Payable
(b) proceeds from sales of investment securities totaling $495,000
(c) $55,000 of revenue received in cash pursuant to a license granted by the Company to Oncology Pharma, Inc
Offset by the costs of operating the business of the Company as well as non recurring cash payment of $800,000 paid in connection with a legal settlement.
As of September 30, 2021 we had Accounts Receivable, Related Party of $213,192 and as of September 30, 2020 we had Accounts Receivable, Related Party of $ 103,192.
The increase in Accounts Receivable, Related Party of approximately 106.6% is attributable to the accrual of $110,000 of minimum royalties and anniversary fees pursuant to a license granted to Zander by Regen Biopharma, Inc.
As of September 30, 2021 we had Prepaid Expenses of $48,144 and as of September 30, 2020 we had prepaid expenses of $28.
The increase in Prepaid Expenses is primarily attributable to an agreement entered into by and between the Company and a third party for the provision of Research and Development services. The term of the agreement is from July 1, 2021 to July 1, 2023. The total consideration due of $55,000 was paid to the contractor as of July 1, 2021 and is being expensed over the term of the agreement.
As of September 30, 2020 we had Notes Receivable, Related Party of $0 and as of September 30, 2021 we had Notes Receivable, Related Party of $ 5,396.
The increase in Notes Receivable is attributable to $5,396 loaned by the Company during the quarter ended June30, 2021 to Zander Therapeutics, Inc. an entity under common control.
As of September 30, 2020 we had Investment Securities ( Not Related Party) of 0 and as of September 30,2021 we had Investment Securities ( Not Related Party) of $198,006.
During the quarter ended June 30, 2021 the Company was paid 50,000 common shares of Oncology Pharma, Inc. pursuant to an agreement entered into by and between KCL Therapeutics, Inc. ( a wholly owned subsidiary of the Company) and Oncology Pharma, Inc. whereby Oncology Pharma, Inc. was granted a license for the development and commercialization of certain intellectual property (“License IP”) for the treatment in humans of colon cancer for a term of fifteen years from April 7, 2021.
During the quarter ended June 30, 2021 13,700 of the aforementioned common shares were sold to an unrelated party for $300,000 cash.
During the quarter ended September 30, 2021 18,000 of the aforementioned common shares were sold to an unrelated party for $195,000 cash.
As of September 30, 2021 18,300 common shares of Oncology Pharma, Inc. constitute the sole investment securities other than shares of Zander Therapeutics, Inc. held by the Company.
On September 30, 2021 the Company revalued 18,300 common shares of Oncology Pharma, Inc. at the closing price of the common shares on the OTC Pink market.
As of September 30, 2020 we had Accounts Payable of $110,486 and as of September 30,2021 we had Accounts Payable of $91,498. The decrease in Accounts Payable of approximately 17% is primarily attributable to payment of $16,745 of payable due to the Company’s Transfer Agent offset by expenses incurred as a result of services provided by the Company’s Resident Agent as well as payment of expenses related to services provided by a patent attorney.
As of September 30, 2021 we had Notes Payable of $1,429,179 and as of September 30, 2020 we had Notes Payable of $62,127. The increase in Notes Payable of approximately 2200.42% is attributable to the issuance of a Note in the principal amount of $1,500,000 on September 17, 2021 of which $75,000 was retained by the Holder through an Original Issue Discount (“OID”) for due diligence and origination related to this transaction. The OID is being amortized by the Company over the term of the Note
As of September 30, 2020 we had Accrued Interest Payable of $830,061 and as of September 30, 2021 we had Accrued Interest Payable of $954,861.
The increase in Accrued Interest Payable of approximately 15 is attributable to additional interest accrued but unpaid during the year ended September 30,2021 on Notes and Convertible Notes issued by the Company offset primarily by conversion of interest accrued but unpaid due to holders of Convertible Notes Payable into equity securities of the Company during the same period.
As of September 30, 2020 we had Accrued Payroll of $1,189,319 and as of September 30, 2021 we had Accrued Payroll of $1,266,679. The increase of approximately 6.5% is attributable to $77,360 of salary accrued but unpaid to the Company’s former Chief Financial Officer.
As of September 30, 2020 we had Accrued Rent of $23,548 which was paid by the Company during the year ended September 30, 2021.
As of September 30, 2020 we had a Derivative Liability of $2,634,215 and as of September 30, 2021 we had a Derivative Liability of $6,892,477.
The increase in Derivative Liability of approximately 162% is attributable to the recognition by the Company of embedded derivatives on Convertible Notes Payable with an aggregate face value of $1,795,973 outstanding as of September 30, 2021. Recognition of embedded derivatives on Convertible Notes Payable with an aggregate face value of $2,089,377 outstanding as of September 30, 2020 were recognized by the Company during the fiscal year ended 2020.
As of September 30, 2021 we had Convertible Notes Payable, Net of Unamortized Discount, of $2,152,811 and as of September 30, 2020 we had Convertible Notes Payable, Net of Unamortized Discount, of $2,541,766.
The decrease in Convertible Notes Payable, Net of Unamortized Discount, of approximately 15 % is primarily attributable to conversions of principal indebtedness into the equity securities of the Company offset by amortization of $47,063 of Discounts on Convertible Notes.
As of September 30, 2021 we had Unearned Income of $1,843,806 and as of September 30, 2020 we had Unearned Income of $0.
Unearned Income as of September 30,2021 represents that portion of $1,905,000 of license fees paid during the quarter ended June 30, 2021 to be recognized as revenue over the 15 year term of the licenses granted in accordance with ASC 606.
Material Changes in Results of Operations
Revenues from continuing operations were $110,000 for the twelve months ended September 30, 2020 and $171,194 for the same period ended 2021. $110,000 of revenue recognized during the years ended September 30, 2021 and September 30, 2020 consisted of $100,000 related to an anniversary expense receivable pursuant to a license granted by the Company to Zander Therapeutics, Inc. and $10,000 of minimum royalties recognized during the twelve months ended September 30 2021 and 2020 respectively pursuant to the same license. $61,194 of revenue recognized during the year ended September 30, 2021 were recognized pursuant to licenses granted to Oncology Pharma,Inc.
With regards to the aforementioned license granted to Zander On December 17, 2018 Regen Biopharma, Inc.(“Licensor”) , KCL Therapeutics, Inc. (“Assignee”) and Zander Therapeutics, Inc. (“Licensee”) entered into a LICENSE ASSIGNMENT AND CONSENT AGREEMENT whereby, with regards to certain intellectual property which was assigned by Regen Biopharma, Inc.(“Assigned Properties”) to its wholly owned subsidiary KCL Therapeutics, Inc., Licensor hereby transfers and assigns to Assignee all rights, duties, and obligations of Licensor under the Agreement with respect to the Assigned Properties , and Assignee agrees to assume such duties and obligations thereunder and be bound to the terms of the Agreement with respect thereto.
The Company recognized an Operating Loss of $200,771 during the year ended September 30, 2021 whereas the Company recognized an Operating Loss of $209,317 for the same period ended September 30, 2020. The Company recognized a Net Loss of $6,765,233 for the twelve months ended September 30, 2021 whereas the Company recognized Net Income of $3,623,736 for the same period ended 2020. Contributing factors to the difference between the periods were:
(a) The recognition of a Derivative Loss of $4,264,975 during the twelve months ended September 30,
(b) The recognition of Derivative Income of $4,566,669 during the twelve months ended September 30,
(c) recognition of an $800,000 expense related to a legal settlement during the year ended September 30,2021
(d) Recognition of $524,960 of realized losses on sales of Investment Securities during the year ended September 30,2021
(e) Recognition of $632,094 of unrealized losses on sales of Investment Securities during the year ended September 30, 2021.
As of September 30, 2021 we had $727,162 in cash on hand and current liabilities of $14,697,976 such liabilities consisting of Accounts Payable, Notes Payable, Convertible Notes Payable , Derivative Liability Recognized, Unearned Income and Accrued Expenses. We feel we will not be able to satisfy our cash requirements over the next twelve months and shall be required to seek additional financing.
As of September 30, 2021 the Company was not party to any binding agreements which would commit Regen to any material capital expenditures.